Compare Novo Nordisk A/S (NVO) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Plug Power Inc — how do they compare? Novo Nordisk A/S trades at $38.21 (market cap $165.31B), while Plug Power Inc trades at $1.75 (market cap $2.42B). The key difference: Novo Nordisk A/S is far larger — about 68.3× Plug Power Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Plug Power Inc for 41 Days on average.
| NVO | PLUG | |
|---|---|---|
Market Cap | $165.31B | $2.42B |
Volume | 11,432,838 | 53,851,702 |
Sector | Health | Industrials |
52-Week High | $63.98 | $4.14 |
52-Week Low | $35.29 | $1.73 |
Typical Hold Time | 116 Days | 41 Days |
Enterprise Value | $179.56B | $3.29B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Plug Power (PLUG) trades at $1.78, down 4.3% today, with a bearish technical outlook and negative earnings momentum. The company continues to report significant losses with a net income margin of -220.59% and negative cash flow, though recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels. Analyst consensus shows mixed sentiment with 44.7% buy ratings and a $3.13 price target, representing 76% upside potential from current levels.
While PLUG shows potential through hydrogen infrastructure expansion and recent contract wins, the investment case remains high-risk due to persistent negative profitability, cash burn, and competitive pressures. The stock trades near analyst low targets, suggesting limited downside protection, making it suitable only for speculative investors comfortable with substantial volatility and execution risk in the clean energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
